← Back to all trials
Not Yet Recruiting
NCT05703243
Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Liquid Molecular Testing Panel in the Community Setting ("DINOSAur II")
Conditions: Stage III Solid Tumors, Stage IV Solid Tumors
Sex: All
Ages: 18 Years – N/A
Enrollment: 572
Sponsor: Glendale Adventist Medical Center d/b/a Adventist Health Glendale
Summary
To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive l i q u i d molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.
Eligibility Criteria
Inclusion Criteria:Patients who have given informed consent in accordance with the methods and procedures of this studyDiagnosis of cancer (stage 3 and stage 4; solid tumors only) requiring medical carePatients who have not received treatment related to his/her cancerPatients who are willing to sign a release of medical records to the research teamMale and female patients ≥18 years of agePatients under oncology careSufficient clinical status for collection of blood sample within usual careExclusion Criteria:Patients considered minors in the jurisdiction where the protocol is conductedPatients who are prisoners and pregnant womenPatients who cannot provide consent and did not sign a power of attorney
Source: ClinicalTrials.gov (NCT05703243). StuddyBuddy aggregates publicly available trial information.
